#171 – Steve Austad, Ph.D.: The landscape of longevity science: making sense of caloric restriction, biomarkers of aging, and possible geroprotective molecules
“I never thought [extending the human lifespan] was going to happen because we got better at treating cancer or we got better at preventing heart disease. I always thought it was going to happen because we would develop something … that would fundamentally change the rate of aging. And we haven’t developed that yet. We’ve got a lot of clues and I think we’re getting closer and closer and closer.” —Steve Austad
How long can we live?; suggested listening
Revisiting the podcast archive
Rapamycin: one of my favorite stories; Ryan Lochte’s flip side on missing Olympic redemption
A few things worth checking out: 07-18-2021
#123 – Joan Mannick, M.D. & Nir Barzilai, M.D.: Rapamycin and metformin—longevity, immune enhancement, and COVID-19
“I think what the mTOR inhibitors are doing is not stopping people from getting infected [with a virus], but if you get infected, there’s a better immune response and your symptoms will be milder.” — Joan Mannick
#118 – Lloyd Klickstein, M.D., Ph.D.: Rapamycin, mTOR inhibition, and the biology of aging
“Our approach is to address serious aging-associated diseases, and if we’re successful, the side effect will be longevity.” — Lloyd Klickstein
Qualy #61 – Rapamycin in cancer treatment
Today’s episode of The Qualys is from podcast #10 – Matt Kaeberlein, Ph.D.: rapamycin and dogs — man’s best friends?…